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Abstract  32 
Background: Paternal zygosity testing is used to determine the hemi- or 33 
homozygosity of RHD in pregnancies at risk of hemolytic disease of the newborn and 34 
fetus (HDFN). Currently, this is achieved using real-time PCR or the RH box PCR, 35 
which can be difficult to interpret and unreliable, particularly for black African 36 
populations.  37 
Method: DNA samples extracted from 58 blood donors were analysed using two 38 
multiplex reactions for RHD specific targets against a reference (AGO1) to determine 39 
gene dosage using digital PCR. Results were compared to serological data and the 40 
correct genotype for two discordant results was determined by long range-PCR, next 41 
generation sequencing and conventional Sanger sequencing. 42 
Results: The results show clear and reliable determination of RHD zygosity using 43 
digital PCR and revealed that four samples did not match the serologically predicted 44 
genotype. Sanger sequencing and long range-PCR followed by next generation 45 
sequencing revealed that the correct genotypes for samples 729M and 351D, which 46 
were serologically typed as R1R2 (DCe/DcE), were R2r’ (DcE/dCe) for 729M and R1r’’ 47 
(DCe/dcE), R0ry (Dce/dCE) or RZr (DCE/dce) for 351D, in concordance with the 48 
digital PCR data.  49 
Conclusion: Digital PCR provides a highly accurate method to rapidly define blood 50 
group zygosity, and has clinical application in the analysis of Rh phenotyped or 51 
genotyped samples. The vast majority of current blood group genotyping platforms 52 
are not designed to define zygosity, and thus this technique maybe used to define 53 
paternal RH zygosity in pregnancies at risk of HDFN, and distinguish between homo- 54 





Of the 36 blood group systems Rh is the most complex at the genetic level and is the 57 
major cause of hemolytic disease of the fetus and newborn (HDFN) and a major 58 
cause of transfusion reactions during alloimmunization events. The RH genes, RHD 59 
and RHCE, are well characterized at the genetic level, with a combination of SNPs in 60 
RHCE being responsible for the C/c and E/e polymorphisms, whilst gene deletion 61 
and hybrid RHD-RHCE genes are responsible for D-negative phenotypes, plus 62 
SNPs and hybrid genes being responsible for partial and weak D phenotypes (1, 2). 63 
All known mutations have been well catalogued and best described in the 64 
RhesusBase resource (3). 65 
Paternal RHD zygosity testing is important for prenatal management of 66 
alloimmunized women. Where fathers are homozygous D- there is no risk of HDFN 67 
for the current pregnancy or subsequent pregnancies that may follow. Pregnancies 68 
to homozygous D+ fathers (with the assumption of paternity) will by definition carry 69 
RhD positive fetuses, and can be considered for more focused clinical management. 70 
For hemizygous D+ fathers non-invasive prenatal testing (NIPT) is required for a 71 
definitive diagnosis. 72 
Previously published methods for RHD zygosity testing have included real-time PCR 73 
(qPCR) assessment of RHD gene dosage, assessment of the hybrid Rhesus box 74 
found in D-negative individuals with the RHD gene deletion genotype and allele-75 
specific PCR methods, as well as mass spectrometry-based methods. (2, 4-10). 76 
Zygosity testing targeting the hybrid Rhesus box found in RHD-deletion type cde 77 
haplotypes is complicated because of differences in the hybrid box amongst 78 




The incidence of common RH haplotypes in Caucasian, African black and Asian 80 
populations has been defined serologically. In RHD positive individuals the DCe 81 
haplotype is prevalent in Asian (73%) and Caucasian (42%) populations, but in 82 
African black populations the Dce haplotype has a higher incidence (59%) (12). RHD 83 
negative individuals are rarely found in Asian populations (<4%), but the dce 84 
haplotype is frequently found in Caucasian (39%) and African black (20%) 85 
populations (12). Rare haplotypes such DCE, dCe, dcE and Dce are considerably 86 
less prevalent with frequencies of 0.24%, 0.98%, 1.19% and 2.57% respectively, in 87 
Caucasian populations (12). However, it has been difficult to define the precise 88 
population frequencies of the various RH haplotypes due to the inability to 89 
differentiate between hemi- or homozygous individuals. For example, an individual 90 
with the phenotype DCe would be designated as the most common presumed 91 
genotype DCe/DCe rather than DCe/dCe. Thus presumed genotype, based on 92 
probability, is the manner in which donor and patient red cells are labelled. Zygosity 93 
determination of the above would define which presumed genotype (DCe/DCe or 94 
DCe/dCe) (two copies of the RHD gene versus one copy of the RHD gene) is carried 95 
by a particular individual. 96 
Previously we have applied digital PCR (dPCR) to the analysis of free fetal DNA 97 
derived from maternal plasma (13). In this study we have utilized dPCR as a more 98 
accurate quantitative PCR method than conventional qPCR to define RHD zygosity. 99 
We found rare haplotypes in a relatively small cohort of samples and identified that 100 
for three samples (plus one weak D sample) their predefined and labelled presumed 101 
genotype was indeed incorrect.  102 




Study Participants   104 
Human whole blood samples (n= 79) were supplied by the National Health Service 105 
Blood and Transplant (NHSBT) (Bristol, UK) (donated with informed consent) and 106 
transported to NHS Plymouth Hospitals Trust, Plymouth, UK for collection.  107 
Sample Processing  108 
Samples were processed in two ways. Human whole blood samples (n = 25) were 109 
collected in EDTA tubes (5-10 mL total blood volume) and centrifuged at 1 600xg for 110 
10 minutes (min) at room temperature. The plasma was carefully removed and 111 
transferred to a 15 mL tube. The plasma was then re-centrifuged at 16 000xg for 10 112 
min. All samples were processed within 48 to 96 hours of collection and plasma 113 
aliquots (1 mL) were stored at -80°C.  114 
Human whole blood samples (n = 54) were collected in EDTA tubes (5-10 mL total 115 
blood volume) and centrifuged at 2 500xg for 10 min at room temperature.  The buffy 116 
coat layer was carefully removed and transferred to a 1.5 mL tube for immediate 117 
processing to genomic DNA (gDNA).  All blood samples were processed within 48 to 118 
96 hours of blood collection. 119 
DNA extraction from plasma  120 
Plasma extractions were performed as non-pregnant controls from maternal plasma 121 
experiments (13) and were further utilised in this study. DNA was extracted from two 122 
1 mL aliquots of plasma using the QIAamp Circulating Nucleic Acid (CNA) kit 123 
(Qiagen, West Sussex, UK) using the QIAvac 24 Plus (Qiagen). The extraction 124 
process was as the manufacturer’s protocol and each sample was eluted in 60 L 125 




RNase treatment was used. Following DNA extraction, samples were quantified on 127 
the Qubit® 2.0 Fluorometer (Life Technologies, Paisley, UK) using the Qubit® 128 
dsDNA HS assay kit (Life Technologies). Samples were stored at -20°C as 60 µL 129 
aliquots for up to four weeks. 130 
DNA extraction from buffy coat  131 
For RHD intronic SNP sequencing, gDNA was extracted from buffy coats using the 132 
QIAamp DNA Blood Mini kit (Qiagen) according to the manufacturer’s instructions.  133 
DNA was eluted in 200 µL Buffer AE and incubated at room temperature for 5 min 134 
before centrifugation at 11 865xg for 1 min.  For the RHD long-range PCR (LR-135 
PCR), gDNA was extracted from buffy coats using the Gentra® Puregene® Blood kit 136 
(Qiagen) according to the manufacturer’s instructions for RNA-free DNA. As the 137 
buffy coat contained red blood cells, RBC Lysis Solution was used.  Each sample 138 
was eluted by adding 300 μL of DNA hydration solution and mixed vigorously for 5 139 
seconds, followed by incubation at 65°C for 1 hour. The tube was then incubated at 140 
room temperature overnight with gentle shaking in order to mix the gDNA with the 141 
DNA hydration solution. Finally, the pure gDNA was transferred into a new 1.5 mL 142 
tube and stored at −20°C. Following DNA extraction, samples were quantified on the 143 
Qubit® 2.0 Fluorometer (Life Technologies) using the Qubit® double-stranded DNA 144 
(dsDNA) High Sensitivity assay kit (Life Technologies). 145 
PCR Primers and Probes for dPCR   146 
Two multiplex reactions were tested on the QX100™ droplet digital PCR (ddPCR) 147 
platform (Bio-Rad Laboratories, Herfordshire, UK) for RH zygosity testing (Table 1), 148 
as previously described in Sillence et al. (13). The oligonucleotide sequences (High 149 




and amplicon sizes for all target (FAM-labelled) and reference (HEX-labelled) 151 
regions are shown in Table 1. Prior to zygosity testing, primer annealing 152 
temperatures (56°C to 60°C) were optimised for both multiplex reactions (see 153 
Supplemental Figure 1). The results in Supplemental Figure 1a showed successful 154 
droplet separation of the RHD5 (FAM) target at all annealing temperatures, but the 155 
AGO1 (HEX) reference showed sub-optimal separation at 60°C. Droplet separation 156 
for the RHD7 (FAM)/ AGO1 (HEX) multiplex reaction (see Supplemental Figure 1b) 157 
demonstrated the same pattern as previously discussed for the RHD5 (FAM)/AGO1 158 
(HEX) multiplex reaction. However, the optimal ratio was visible at 58.4°C (0.995). 159 
Therefore 58°C was determined to be the optimum annealing temperature for both 160 
multiplex reactions. 161 
dPCR  162 
The dPCR reactions were conducted in duplicate and run on the QX100™ Droplet 163 
Generator (Bio-Rad) following manufacturer’s instructions (see Sillence et al. (13)). 164 
Plasma extracted samples were not diluted and a standard volume of template DNA 165 
(5 µL) was added. Samples extracted from buffy coat were diluted and 50ng of DNA 166 
was added to each 20 µL reaction and a non-template control (NTC) was included in 167 
each assay.  168 
Data Analysis for dPCR  169 
The raw fluorescent data from the ddPCR platform was analysed using the Bio-Rad 170 
QuantaSoft v1.2 software. Once thresholds for each sample had been set manually 171 
using the 1D amplification plot, positive and negative droplets were determined (see 172 
Supplemental Figure 1). The concentration was then determined by the software 173 




target (RHD5-FAM and RHD7-FAM) over the reference (AGO1-HEX) for each 175 
sample was calculated as follows: FAM (copies/ µL)/HEX (copies/ µL). All statistical 176 
analysis was performed using Mann Whitney U Test (SigmaPlot Version 12.5) and 177 
significance was accepted at p<0.05. 178 
RHD LR-PCR and Next generation sequencing (NGS) 179 
gDNA samples from blood donors of different phenotypes were tested using LR-PCR.  180 
Three PCR products were designed to cover the entire RHD gene (Table 2).  The 181 
HPLC-purified primers were from Eurofins MWG Operon (London, United Kingdom).  182 
The PCR reaction contained a final 1x concentration of PrimeSTAR GXL Buffer 183 
(Takara, Japan), 200 μM dNTP mixture, 0.2 μM of each primer and 1.25 unit 184 
PrimeSTAR GXL Polymerase per 50 μL and 500ng DNA  per reaction. A two-step 185 
protocol was performed as 25 cycles of 98°C for 10 s and 68°C for 24 min, final hold 186 
at 4°C.The amplicons were purified on 0.5% w/v agarose gel in 1X TAE buffer. The 187 
long amplicons were purified by Agencourt® AMPure® XP beads (Beckman Coulter, 188 
High Wycombe, UK) to ensure removal of primer dimers, polymerase and free 189 
nucleotides.  The samples were eluted in 50 µL nuclease-free water.  Purified 190 
amplicons were quantified by Qubit® dsDNA Broad-Range assay kit (Life 191 
Technologies) to allow the starting concentration of the sequencing libraries to be 192 
100 ng.  Following quantification, enzymatic fragmentation was completed using the 193 
Ion XpressTM Plus Fragment Library Kit (Life Technologies) resulting in fragments of  194 
~200bp.  Next, the fragments were ligated with barcoded adapters, which add about 195 
70bp to the fragments. P1 and Ion XpressTM Barcode X adapters from the Ion 196 
XpressTM Barcode Adapters Kit (Life Technologies) were used to distinguish the 197 
samples when pooled prior to sequencing. The adapter-ligated library was size 198 




each step (fragmentation, ligation and size selection), purification was conducted 200 
using magnetic beads and the integrity, size distribution, concentration and quality of 201 
the library in those steps was checked using the Agilent® 2100 Bioanalyzer® 202 
instrument and Agilent High Sensitivity DNA Kit (Agilent Technologies UK Limited, 203 
Stockport, UK). 204 
Template-positive ion sphere particles (ISPs) containing clonally amplified DNA were 205 
prepared by the Ion Personal Genome Machine™ (PGMTM) Template OT2 200 Kit 206 
(for 200 base-read libraries) (Life Technologies) with the Ion OneTouchTM 2 System. 207 
Then the percentage of template-positive ISPs was checked by the Ion Sphere™ 208 
Quality Control assay (Life Technologies, Paisley, UK) on the Qubit® 2.0 209 
Fluorometer (Life Technologies) and then enriched by the Ion OneTouch™ ES 210 
Instrument before loading onto a 316TM chip.  Sequencing was carried out using the 211 
Ion PGMTM Sequencing 200 Kit v2 (Life Technologies) and the Ion Torrent PGMTM. 212 
Bioinformatics for RHD LR-PCR  213 
Torrent Suite™ Software Version 4.4 was utilised in order to generate a summary 214 
sequencing report indicating the number of reads generated by the sequencer, the 215 
percentage of chip loading and the sequencing files. The FastQC software was run 216 
to assess the quality control across the reads generated (17). The sequencing 217 
samples were aligned to the human genome reference sequence (hg19) using the 218 
Binary Alignment/Map (BAM) and were visualised using Integrative Genome Viewer 219 
(IGV) Version 2.3.46.  220 
The samples were annotated using the Variant Call Format (VCF) files to obtain the 221 
SNPs and indels to analyse the genotype and predict the phenotype. Antigens were 222 




Factsbook (18). Each antigen was determined by its chromosomal location, the type 224 
of variant (SNP or indel), gene, the reference nucleotide, the changing nucleotide, 225 
depth of coverage, the transcript used in analysis based on the NCBI database, the 226 
location of the variant (intronic or exonic), codon, an exon number of that variant, an 227 
amino acid substitution and the position of the nucleotide change. The SeattleSeq 228 
Annotation tool 141 site was used to annotate the sequencing data of the LR-PCR 229 
approach (19). By using Browser Extensible Data (BED) files, the bedtools website 230 
was used to mask the RHCE gene in order to analyse the RHD gene (20). The 231 
RHCE gene was annotated by ‘Ns’ on its sequencing nucleotides. 232 
RHD Intronic SNP sequencing 233 
gDNA samples from blood donors of different phenotypes were tested. RHD-specific 234 
primers amplified the regions around the intronic SNPs (Table 2). Two different 235 
enzymes were used, BioMix™ 2X master mix (Bioline Reagents Limited, United 236 
Kingdom) or Q5® Hot Start High-Fidelity 2X Master Mix, (New England Biolabs, 237 
United Kingdom). A 50 μL PCR reaction was prepared containing 1X master mix, 238 
200ng of DNA template, 1 μM of each of the primers. Cycling was carried out on a 239 
Veriti Thermal Cycler (Life Technologies) following optimised conditions; 95°C for 10 240 
min, 35 cycles of 95°C for 30 s and optimised annealing temperature for 1 min, 72°C 241 
for 30 s, followed by a final 72°C step for 10 min. To validate PCR amplification, PCR 242 
products were run on a 1% w/v agarose gel in 1x TAE buffer. PCR products were 243 
purified using the QIAquick Gel Extraction Kit, (Qiagen Ltd, West Sussex, United 244 
Kingdom) according to the manufacturer’s instructions. PCR amplicons were 245 
subjected to Sanger sequencing by Eurofins Genomics. Results were aligned with 246 
the human genome reference sequence (hg19). CodonCode Aligner 6.0 software 247 




Results  249 
Determination of RHD Zygosity  250 
For zygosity testing, the presence or absence of RHD amplification on the ddPCR 251 
platform was used to determine whether the samples were RHD negative or RHD 252 
positive, respectively. The mean number of copies per droplet for all molecules was 253 
0.15 (0.03 – 0.57) for plasma DNA samples and 0.39 (0.05 – 0.69) for buffy coat 254 
DNA samples. The ratio of RHD5 (FAM)/ AGO1 (HEX) and RHD7 (FAM)/ AGO1 255 
(HEX) generated by the QuantaSoft v1.2 Software was then used to determine 256 
whether the D-positive samples were hemizygous or homozygous for the RHD gene. 257 
Samples showing ratios close to 1 were determined to be homozygous RHD positive 258 
and samples with ratios closer to 0.5 were classified as hemizygous RHD positive 259 
(Figure 2).  260 
The results demonstrated that the assay worked equally well on cell free DNA and 261 
gDNA for zygosity determination (Table 3) (Figure 2). Three rr control samples were 262 
tested (147J, 1660, 7807) and results demonstrated amplification of only the 263 
reference (AGO1), giving a ratio of zero (Figure 2). The hemizygous D+ R0r 264 
(Dce/dce) (n = 8), R1r (DCe/dce) (n = 12) and R2r (DcE/dce) (n = 1) samples 265 
demonstrated ratios close to 0.5 as expected (Table 3) (Figure 2), except for sample 266 
1777. Sample 1777, previously classified by serology as being phenotypically R1r 267 
(DCe/dce), expressed ratios of 0.97 and 1.04 for the RHD5 and RHD7 multiplex 268 
reactions, respectively (Table 3). This result contradicted previous serological 269 
classification and indicated that the sample expressed two copies of the RHD gene. 270 
Therefore, it is more feasible that this sample actual expresses the R1R0 (DCe/Dce) 271 




R1R2 (DCe/DcE) (n = 10) and R2RZ (DcE/DCE) (n = 1) samples were expected to 273 
generate a ratio close to 1, and this was achieved in 90% of samples. Sample 087W 274 
was serologically typed as expressing the R2R2 (DcE/DcE) phenotype. However, the 275 
dPCR results demonstrate that this sample is hemizygous for the RHD gene, since 276 
both assays illustrated a ratio close to 0.5 (Figure 2). Therefore, it is likely that 277 
sample 087W has the R2r’’ (DcE/dcE) genotype as opposed to the R2R2 (DcE/DcE) 278 
serologically predicted genotype. Further sequencing analysis was required to 279 
determine the actual genotype of the incorrectly labelled R1R2 samples (729M and 280 
351D) (Figure 2).   281 
RHD intronic polymorphisms  282 
We sequenced the complete RHD gene from individuals with defined RH genotypes 283 
using LR-PCR (Table 2) and we identified several intronic polymorphisms that 284 
closely correlated with the individuals DCE status. On further analysis using Sanger 285 
sequencing, five SNPs showed complete concordance when scrutinised using 286 
primers flanking these regions (Tables 2 and 4). 287 
Comparison of RHD intronic polymorphisms and zygosity 288 
Two of the R1R2 (DCe/DcE) presumed genotype samples tested (729M and 351D) 289 
expressed ratios close to 0.5 for both assays (Figure 2b). Since sample 729M has 290 
also been typed as weak D, it is highly unlikely that this sample is homozygous RHD 291 
positive. Therefore, it is clear this sample has been misclassified as R1R2, but we 292 
could not ascertain whether the true genotype for sample 729M was R2r’ (DcE/dCe), 293 
RZr (DCE/dce), R0ry (Dce/dCE) or R1r’’ (DCe/dcE). Consequently, LR-PCR coupled 294 
with NGS revealed that sample 729M displayed the exon 9 Gly385Ala 1154G>C 295 




multiple RHD intronic SNPs which appear to be associated with the R2 (DcE) 297 
haplotype, which demonstrates that sample 729M is likely to be R2r’ (DcE/dCe) 298 
(Table 4). Sample 351D was not typed serologically as weak D but the dPCR data 299 
shows that only one copy of RHD is present (Figure 2b) and thus the genotype must 300 
either be R2r’ (DcE/dCe), RZr (DCE/dce), R0ry (Dce/dCE) or R1r’’ (DCe/dcE). This 301 
sample did not show the R2 associated RHD intronic SNPs and hence is likely to 302 
have a genotype of R1r’’ (DCe/dcE), R0ry (Dce/dCE) or RZr (DCE/dce).   303 
Discussion  304 
RHD zygosity assignment has proved to be a useful diagnostic tool in the clinical 305 
management of HDFN. Here, determination of homozygous (RHD/RHD) fathers 306 
would give confidence (assuming paternity) of prenatal prediction of D-positive 307 
fetuses, and signal where further monitoring or administration of prophylactic anti-D 308 
maybe required. Without doubt, the most appropriate technique would be the 309 
assessment of D-positive infants directly by analysis of free fetal DNA in maternal 310 
plasma. However, in repeat pregnancies fathered by RHD/RHD homozygotes 311 
maternal plasma testing would not be necessary as the fetus would invariably be D-312 
positive. This is of course with the caveat that paternity can be assured during the 313 
maternal consenting process.  Previous methods have utilised qPCR (4, 7-9), MLPA 314 
(6), mass spectrometry (10) and analysis of the Rhesus box (2, 5, 11). However, as 315 
we have previously mentioned, individuals have been described that confound 316 
zygosity testing when relying on analysis of the Rhesus box repeat sequences (11).  317 
Here we describe a rapid and accurate further method for defining RHD zygosity.  318 
We have used this on a small cohort of phenotyped blood samples and 319 




and in addition, to correct presumed phenotype in blood donors which is presently 321 
dependent on phenotype prediction.  322 
In three samples we have analysed, and a weak D sample, we have clearly 323 
demonstrated homo and hemizygosity for RHD, which was not in concordance with 324 
predicted phenotype. The vast majority of current genotyping methods (22-27) are 325 
not able to define zygosity (except the study by Gassner et al. (10) or unless an 326 
assessment of intronic RHD-specific SNPs is performed, some of which are 327 
described in this paper). Our description of candidate SNPs that define the RHD 328 
gene within the DcE haplotype will also provide a method to differentiate homo or 329 
hemizygosity, and we have candidate RHD intronic SNPs that define the DCe and 330 
Dce RHD genes (in preparation). However, much more work on a larger number of 331 
donors (including the testing of rare RH haplotypes) has to be done before these 332 
candidate RHD intronic SNPs can be confirmed as being truly DCe and Dce specific. 333 
Nevertheless, these RHD intronic SNPs may not be able to differentiate between 334 
DcE/DcE and DcE/dcE; DCe/DCe and DCe/dCe; and Dce/Dce and Dce/dce 335 
genotypes, however, the dPCR method described here is able to facilitate this 336 
(differentiating homo and hemizygosity).  Clearly, for these candidate SNPs to have 337 
clinical utility, a larger cohort of phenotyped samples will require sequencing. We 338 
have subsequently performed such an analysis on 37 Rh phenotyped individuals, 339 
and have found complete concordance with the five DcE-associated candidate SNPs 340 
described in this study. We have identified a further 11 such candidate SNPs that 341 
also are in concordance with DcE genotype. (WAT, KAS, AJH, MK, TEM and NDA, 342 
manuscript in preparation).  We are currently investigating a number of Rh variants 343 




This method provides a quick and accurate platform for rapid determination of RHD 345 
zygosity. In this small cohort of samples, we would be unlikely to see rare haplotypes 346 
such as DCE, dCe, dcE and Dce. However, both dCe and dcE haplotypes were 347 
identified. Further zygosity-based studies are clearly necessary to reassess the 348 
population frequencies of these D-negative haplotypes. It is important also to 349 
consider that fathers that are RHD hemizygous DCe/dCe or DcE/dcE may pass the 350 
dCe or dcE haplotypes to their children, and these fetuses may be at risk of HDFN 351 
due to anti- C or G (28) or anti-E (29). Fetal genotyping for inheritance of both Rh C 352 
and Rh E has been routinely performed using maternal plasma and should therefore 353 
be used in such cases where hemizygosity has been defined. We believe that the 354 
method we describe here is a useful addition to the diagnostic repertoire available to 355 
the clinician in the management of HDFN. 356 
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Table 1: RHD5, RHD7 and AGO1 oligonucleotide sequences, product size and gene 446 





Primer Sequence (5’ - 3’) 
Dual-Labelled Hydrolysis 
















































*Taken from Finning et al. (15) 448 
**Taken from Fan, et al. (14) 449 




Table 2: RHD intronic SNP and RHD long-range PCR oligonucleotide 451 
sequences, product sizes and corresponding SNP in the RHD gene (hg19 452 
human genome reference sequence, for intronic SNPs). 453 
 454 
Intronic SNPs Intron 
Forward Primer Sequence 
5’-3’ 
































































*Adapted from Legler et al. (16) 456 




Table 3: Zygosity testing results determined by ratio analysis for DNA samples 458 
extracted from both the plasma (cfDNA) and buffy coat (gDNA) of human whole 459 
blood samples. 460 



















rr (dce/ dce) 
1660* 0 0 
Homozygous RHD 
negative 
rr (dce/ dce) 
7807* 0 0 
Homozygous RHD 
negative 
rr (dce/ dce) 
9763* 
R0r (Dce/ dce) 
 
0.45 0.43 Hemizygous R0r (Dce/ dce) 
069F* 0.5 0.49 Hemizygous R0r (Dce/ dce) 
740B* 0.47 0.46 Hemizygous R0r (Dce/ dce) 
258D* 0.51 0.51 Hemizygous R0r (Dce/ dce) 
(079*)* 0.51 0.50 Hemizygous R0r (Dce/ dce) 
649B* 0.5 0.5 Hemizygous R0r (Dce/ dce) 
8931* 0.49 0.49 Hemizygous R0r (Dce/ dce) 
5784* 0.49 0.50 Hemizygous R0r (Dce/ dce) 
065S* 
R1r (DCe/ dce) 
 
0.49 0.49 Hemizygous R1r (DCe/ dce) 
118Z* 0.5 0.49 Hemizygous R1r (DCe/ dce) 
1226* 0.52 0.51 Hemizygous R1r (DCe/ dce) 
1306* 0.51 0.53 Hemizygous R1r (DCe/ dce) 
1777* 0.97 1.04 
Homozygous RHD 
positive 
R1R0 (DCe/ Dce) 
180H* 0.52 0.52 Hemizygous R1r (DCe/ dce) 
181F* 0.52 0.49 Hemizygous R1r (DCe/ dce) 
148R 2 0.50 0.50 Hemizygous R1r (DCe/ dce) 
6418 2 0.51 0.49 Hemizygous R1r (DCe/ dce) 
3093  0.51 0.51 Hemizygous R1r (DCe/ dce) 
572R 2 0.50 0.50 Hemizygous R1r (DCe/ dce) 
7687 2 0.50 0.51 Hemizygous R1r (DCe/ dce) 
5481 2 R2r (DcE/ dce) 0.50 0.51 Hemizygous R2r (DcE/ dce) 
1220* 




R1R1 (DCe/ DCe) 
131Z* 0.99 1.04 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
165F* 0.94 0.9 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
1793* 0.99 1 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
0670* 0.91 0.85 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
1347* 0.99 1.03 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
138R* 0.95 0.98 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
052M 0.99 1.03 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
247X 1.02 1.01 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
078U 0.99 1.01 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
103N 1.01 1.03 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
1461 0.99 1.01 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
877L 1.01 0.98 
Homozygous RHD 
positive 
R1R1 (DCe/ DCe) 
658G 




R2R2 (DcE/ DcE) 
738W 1.02 1.04 
Homozygous RHD 
positive 
R2R2 (DcE/ DcE) 




132H 1.01 1.03 
Homozygous RHD 
positive 
R2R2 (DcE/ DcE) 
689U 0.99 1.01 
Homozygous RHD 
positive 
R2R2 (DcE/ DcE) 
729M 2 
R1R2 (DCe/ DcE) 
 
0.50 0.49 Hemizygous 
R1r’’ (DCe/ dcE)  
or R2r’ (DcE/ dCe) 
896H 0.98 1.03 
Homozygous RHD 
positive 
R1R2 (DCe/ DcE) 
898D 0.99 0.97 
Homozygous RHD 
positive 
R1R2 (DCe/ DcE) 
351D 0.51 0.51 Hemizygous 
R1r’’ (DCe/ dcE)  
or R2r’ (DcE/ dCe) 
9316 1.02 1.01 
Homozygous RHD 
positive 
R1R2 (DCe/ DcE) 
911E 1.02 1.03 
Homozygous RHD 
positive 
R1R2 (DCe/ DcE) 
4195 1.02 1.01 
Homozygous RHD 
positive 
R1R2 (DCe/ DcE) 
645C 1.06 1.03 
Homozygous RHD 
positive 
R1R2 (DCe/ DcE) 
3627 0.99 1.01 
Homozygous RHD 
positive 
R1R2 (DCe/ DcE) 
8873 1.02 1.03 
Homozygous RHD 
positive 
R1R2 (DCe/ DcE) 
746P R2RZ (DcE/ DCE) 1.02 0.99 
Homozygous RHD 
positive 
R1R2 (DCe/ DcE) 
1 Serologically predicted phenotype provided by National Health Service Blood and Transplant (NHS 461 
BT) (Bristol, UK).   462 
2 Sample is Weak D.  463 
*DNA samples tested from plasma.  464 
** The C/c and E/e status based on serological information. Only the D/d genotype was corrected by 465 
dPCR. 466 




Table 4: RHD intronic SNP sequencing and RHD LR-PCR NGS results for a range 468 
of DNA samples. 469 
Intronic 
SNPs in RHD 






dce) (n=1)  
R0r (Dce/ 
dce) (n=8)  
R2R2 (DcE/ 




DcE) (n=5)  
Sample 













3 T/T T T C/C  C  T/C C T 
25,627,066 
C>G        
 rs2986167* 




8 T/T T T C/C C T/C C T 
* Taken from the National Center for Biotechnology Information (NCBI) (16).  470 
The table indicates the serologically inferred genotype of the samples provided by 471 
the National Health Service Blood and Transplant (NHS BT) (Bristol, UK). 472 




Figure 1: LR-PCR products for the Rh blood group system. Three long-range 474 
amplicons (1, 2, and 3) were designed to amplify the entire RHD gene. (a) An RhD-475 
negative sample shows no bands for the RHD LR-PCR in lanes 1, 2 and 3, which 476 
represent the three amplicons.  (b) An RhD-positive sample gives amplification of all 477 
three products, with each product being about 22 kb. 478 
 479 
 480 




Figure 2: Ratio analysis to determine zygosity using two multiplex reactions (RHD5 482 
(FAM)/AGO1 (HEX) and RHD7 (FAM)/AGO1 (HEX) for samples with varying Rh 483 
phenotypes. The grey dotted lines at 0.5 and 1 on the y axis represent the ratio 484 
generated by hemizygous D+ samples and homozygous D+ samples, respectively. 485 
The mean ratio for hemizygous and homozygous D+ positive samples for both 486 
plasma and buffy coat extracted samples (Table 3) illustrated significant difference 487 
(p<0.001). The arrows indicate the samples that illustrated discordant results 488 
compared with the serologically predicted genotype. 489 
 490 




Supplemental Figure 1: Annealing temperature gradient (60°C, 58.4°C, 57.4°C and 492 
56°C) of dPCR for both multiplex reactions (RHD5 (FAM)/AGO1 (HEX) and RHD7 493 
(FAM)/AGO1 (HEX)) using sample 0745 (homozygous for RHD) extracted from 494 
human whole blood and a NTC. a) Optimisation of the RHD5 (FAM) and AGO1 495 
(HEX) multiplex reaction. The results illustrate that separation is visible for both 496 
targets at all annealing temperatures. Marginally greater separation is visible at 497 
56°C, but all annealing temperatures are no more than 0.03-0.04 away from a ratio 498 
of 1. b) Optimisation of the RHD7 (FAM) and AGO1 (HEX) multiplex reaction. The 499 
results illustrate that separation is visible for both targets at all annealing 500 
temperatures. However, optimal separation was determined to be 58.4°C, since this 501 
temperature expressed a ratio closer to 1 (0.995). 502 
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